How big is the Asia-Pacific CDMO Market?

The Asia-Pacific CDMO Market size is expected to reach USD 71.60 billion in 2024 and grow at a CAGR of 8.60% to reach USD 108.17 billion by 2029. Read More

What is the current Asia-Pacific CDMO Market size?

In 2024, the Asia-Pacific CDMO Market size is expected to reach USD 71.60 billion. Read More

Who are the key players in Asia-Pacific CDMO Market?

Samsung Biologics, Jubilant Biosys Ltd, WuXi Biologics, Boehringer Ingelheim Group and Jubilant Biosys Ltd are the major companies operating in the Asia-Pacific CDMO Market. Read More

What years does this Asia-Pacific CDMO Market cover, and what was the market size in 2023?

In 2023, the Asia-Pacific CDMO Market size was estimated at USD 65.44 billion. The report covers the Asia-Pacific CDMO Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific CDMO Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Asia-Pacific CDMO Market Share

Statistics for the 2023 & 2024 Asia-Pacific CDMO market share, created by Mordor Intelligence™ Industry Reports. Asia-Pacific CDMO share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Asia-Pacific CDMO Industry

The Asia-Pacific CDMO Market is fragmented because of the presence of major players like Catalent Inc., Jubilant Biosys Ltd, Samsung Biologics, Boehringer Ingelheim Group, and WuXi Biologics. The other players are adopting acquisition and partnership strategies to enter the market and expand their offerings.

February 2023: Catalent unveiled the completion of the expansion of a facility worth USD 2.2 million to its Clinical Supply in Singapore. The expansion increased the site footprint to 31,000 sq. ft, allowing the installation of 35 new UL freezers. The investment also enabled the facility to support bigger packaging campaigns with additional secondary packaging capacities for ULT products and increased capacity to process biopharmaceutical products and advanced modalities such as mRNA-based vaccines and cell and gene therapies.
June 2023: FUJIFILM Diosynth Biotechnologies announced its intentions to enhance the commercial office in Tokyo to enhance sales support and customer service for contract development and manufacturing services catering to Biologics and Advanced Therapies, specifically targeting pharmaceutical and biotechnology firms based in Asia.